Search results
Results from the WOW.Com Content Network
Pages in category "David Geffen School of Medicine at UCLA faculty" The following 129 pages are in this category, out of 129 total. This list may not reflect recent changes .
The UCLA School of Medicine (also known as the David Geffen School of Medicine at UCLA) is the accredited medical school of the University of California, Los Angeles. Founded in 1951, it is the second medical school in the University of California system after the UCSF School of Medicine .
UCLA Faculty Practice Group, a system of more than 1,200 full-time clinical faculty physicians, who work in primary-care and specialty-care offices throughout the Greater Los Angeles Area; UCLA Health Training Center, an arena and a training center for the Los Angeles Lakers; Tiverton House, a 100-room hotel facility for patients and their families
Ronald Reagan UCLA Medical Center (also commonly referred to as UCLA Medical Center, RRMC or Ronald Reagan) is a hospital located on the campus of the University of California, Los Angeles (UCLA), in Westwood, Los Angeles, California, United States.
100 Stein Plaza UCLA [4] Location: Los Angeles, California, United States of America. Coordinates Website: www.uclahealth.org /eye / ...
Robin Kelley (PhD UCLA 1987)- Distinguished Professor and Gary B. Nash Endowed Chair in U.S. History at UCLA. Mark Kleiman – professor of public policy , expert on crime and drug policy Peter Kollock (1959–2009) – associate professor of sociology, specialist in collaboration and online participation in virtual communities
Faculty of the University of California, Los Angeles − UCLA. Individuals employed as professors at UCLA, including current professors, professors emiriti, and deceased professors. See also: List of University of California, Los Angeles people § Notable faculty
Dennis Joseph Slamon (born August 6, 1948), [1] [2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA.He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.